Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335615 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL8966804 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL18975256 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23014949 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL128978 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23014965 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL130671 | 1.00 | — | — | |
| SCHEMBL130493 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL8907249 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL131692 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111943821-B | Synthesis method of (13 cis, 15 trans) -octadecadienal | 苏州华道生物药业股份有限公司 | 2022-04-05 | — | — | CN | claimed |
| CN-111943821-A | Synthesis method of (13 cis, 15 trans) -octadecadienal | 苏州华道生物药业股份有限公司 | 2020-11-17 | — | — | CN | claimed |
| WO-2014001527-A2 | LIPID ANALYSIS | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2014-01-03 | — | — | WO | claimed |
| US-20260103438-A1 | PROBES AND METHODS TO IDENTIFY LIGANDABLE FATTY ACYLATION SITES FOR THERAPEUTIC TARGET IDENTIFICATION | MASSACHUSETTS GEN HOSPITAL (US) | 2026-04-16 | — | — | US | disclosed |
| WO-2024073486-A9 | PROBES AND METHODS TO IDENTIFY LIGANDABLE FATTY ACYLATION SITES FOR THERAPEUTIC TARGET IDENTIFICATION | THE GENERAL HOSPITAL CORPORATION (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20240360163-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2024-10-31 | — | — | US | disclosed |
| US-12049474-B2 | Nucleoside prodrugs and uses related thereto | EMORY UNIVERSITY (US) | 2024-07-30 | — | — | US | disclosed |
| WO-2024073486-A2 | PROBES AND METHODS TO IDENTIFY LIGANDABLE FATTY ACYLATION SITES FOR THERAPEUTIC TARGET IDENTIFICATION | THE GENERAL HOSPITAL CORPORATION (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2022-09-22 | — | — | US | disclosed |
| EP-4017499-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | Emory University (US) | 2022-06-29 | — | — | EP | disclosed |
| CN-114502172-A | Nucleoside prodrugs and related uses thereof | 爱默蕾大学 | 2022-05-13 | — | — | CN | disclosed |
| EP-1535609-A1 | NF-KB ACTIVATION INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1512397-A1 | O-SUBSTITUTED HYDROXYARYL DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-4440940-A | HYPOLIPIDEMIC AND ANTIATHEROSCLEROTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1984-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | HSD17B10 322/4885MAPT 4429/4885CYP1A2 38/4885 |
| US-20240360163-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | HSD17B10 322/4885MAPT 4429/4885CYP1A2 38/4885 |
| US-12049474-B2 | Nucleoside prodrugs and uses related thereto | PNPO, GSTO1, CYP2C18 | HSD17B10 322/4885MAPT 4429/4885CYP1A2 38/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | HSD17B10 704/4885MAPT 2435/4885CYP1A2 1483/4885 |
| US-20260103438-A1 | PROBES AND METHODS TO IDENTIFY LIGANDABLE FATTY ACYLATION SITES FOR THERAPEUTIC TARGET IDENTIFICATION | ZDHHC2, SPTLC2, SPTLC1 | HSD17B10 74/4885MAPT 2842/4885CYP1A2 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.